Sinopharm has experience with WHO pre-qualification for vaccines. Hence, it should be an issue obtaining WHO pre-qualification for Sinopharm Covid Vaccine.
"Sinopharm and Sinovac both have other vaccines pre-qualified by the WHO. A subsidiary of Sinopharm was the first to receive WHO prequalification for Japanese encephalitis vaccines after years of support from several UN agencies to help it meet the standard. “They know what the WHO wants,” Kim said, adding that China was supplying 80 per cent of the Japanese encephalitis vaccines in Asia."
KUALA LUMPUR, Nov 6 — The government has decreased next year’s budgets for curative care and public health, including deep cuts for cancer and kidney disease treatments, even as Malaysia is facing the greatest public health crisis in history with Covid-19.
Despite a slight 4 per cent increase of the Ministry of Health’s (MOH) allocation from last year to RM31.9 billion in Budget 2021, MOH reduced its medical budget by 20.5 per cent from RM14.2 billion in 2020 to RM11.3 billion in 2021, making wide-ranging cuts across almost all health care services, including a massive 74 per cent decrease for pharmacy and supplies, according to the Estimated Federal Expenditure 2021 document. Pharmacy and supplies refer to drugs and other non-pharmaceutical items like personal protective equipment, IV drips, and syringes, among others.
“ No reason to say mink-related coronavirus mutation will harm vaccine development: WHO Europe chief
On Friday, experts from the Geneva-based WHO also said that there is no evidence at the moment that the mutation of SARS-CoV-2 virus in minks in Denmark will affect the efficacy of future vaccines for COVID-19.”
Healthcare budget is NOT cut. The allocation is divided into different sections in the new budget 2021, get yourselves informed for God sake. Check out Tengku Zafrul's twitter regarding the explanation:
"Denmark, in an unfortunate decision, has decided to kill every mink in the country to stop the spread of mutated coronavirus to humans. The total estimated population of minks in Denmark is around 15 million.
Danish Prime Minister Mette Frederiksen made the decision public on November 4, 2020. He acknowledged that it was a “heavy decision” but the situation required “resolute action.”
SEREMBAN (Nov 7): The government will make advance bookings of Covid-19 vaccines with the over RM3 billion allocation under Budget 2021, said the Science, Technology and Innovation Minister Khairy Jamaluddin Abu Bakar.
He said the ministry is confident that the allocation was sufficient to make an initial order for the vaccine supply which is expected to be secured in the first quarter of next year once approved by the Ministry of Health (MOH).
Dr. Scott Gottlieb told CNBC on Monday the U.S. will still have to experience “the hardest stretch” of the coronavirus pandemic without the benefits of a vaccine, despite news from Pfizer that its candidate is more than 90% effective. “The vaccine is really a 2021 event in terms of when it’s going to provide protective immunity to that initial tranche” of recipients, Gottlieb said on “Squawk Box,” shortly after the Pfizer announcement. “Then in terms of when it would be widely available, I think the hope still is ... you could have a vaccine broadly maybe the end of the second quarter, maybe into the third quarter. You’re looking at having the vaccine available in time for the fall 2021 Covid season.”
Same ol story as Putin Vaccine but until today no vaccine but the case in Russia keep increase. Vaccine will be available next year end of 2021. Dont high hope on politician talk.
Efficacy of Sinopharm vaccine is higher than Pfizer vaccine. Sinopharm vaccine showed 100% efficacy while Pfizer vaccine only showed 90% efficacy.
-----------
US drug maker Pfizer said its mRNA vaccine candidate is more than 90 percent effective, while SINOPHARM's inactivated vaccine SHOWED 100 PERCENT efficacy at one case in Mexico, both are promising results and have brought about hope of wider use in the fight against the coronavirus, experts said.
Pfizer's announcement got world's attention and many news outlets reported it with enthusiasm, but Sinopharm's vaccine, which have been used on 56,000 people who have traveled abroad, none of whom became infected, were challenged by many Western media when the data was released.
The different reaction revealed Western media's double standard on vaccines for China and the US, with an aim to politicize the issue, Chinese experts said.
Pfizer's 90 percent was based on phase III clinical trials while Sinopharm's is based on observation after emergency use. Although the former has greater authority academically, the latter is also a control study, Tao further explained, noting that the fact 56,000 people did not get infected could serve as a reference for the vaccine's efficacy.
But a major challenge for mRNA vaccines is the temperature requirement for storage - minus 70C for long-term stability in comparison to 2-8 C for the majority of other types of vaccine, Tao noted, "Storage and transportation will be very expensive."
Sinovac vaccine is not related to any companies in Malaysia but just wanted to share anyway.
------------ Brazilian politics, US pressure likely behind Chinese vaccine's suspension: experts
The Chinese Foreign Ministry, the Chinese vaccine producer and a Brazilian institute clarified that Brazilian health regulator's decision to halt trials of a Chinese-produced COVID-19 vaccine in Brazil is NOT RELATED TO THE VACCINE ITSELF, after foreign media said the suspension came following a "severe adverse event."
Chinese experts said politicization of vaccine issues by some Brazilian politicians was likely the reason. They said the vaccine trial issue, which is life-saving work amid the COVID-19 pandemic, should not be influenced by Brazilian political disputes or US pressure.
They stressed that the vaccine is essential to fight the virus, but the suspension without a reasonable excuse could slow down the vaccine-development process.
Wang Wenbin, spokesperson of the ministry, said at a press conference on Tuesday we notice that BUTANTAN INSTITUTE, partner of China's Sinovac Biotech in Brazil, has concluded that the reported "adverse event" that caused Brazil's health regulator on Monday to suspend trials of a Chinese-produced vaccine in Brazil was NOT RELATED TO THE VACCINE produced by Sinovac.
SUICIDE halts Brazil trial of Chinese vaccine attacked by Bolsonaro
The trial’s organizers criticized Anvisa’s decision, saying they had not been notified in advance and that there was no reason to stop the trial.
Although a trial volunteer had died, it had nothing to do with the vaccine, Jean Gorinchteyn, Health Secretary for the state of Sao Paulo told a news conference on Tuesday.
“We had an external event that led to the regulator being notified,” Gorinchteyn said. “This vaccine is safe.”
Dimas Covas, the head of Sao Paulo’s medical research institute Butantan, which is conducting the Sinovac trial, said the vaccine had shown no serious adverse effects. Speaking at the same news conference, he said he hoped the trial would be resumed later on Tuesday or Wednesday.
Anvisa said the initial information it received from Butantan had not specified that the death was a SUICIDE.
Administered to more than 100,000 people in China, vaccines developed by public entity SINOPHARM against Covid-19 are in their final stages of testing. Morocco, which is participating to the process, will launch an expanded vaccination campaign in the coming weeks.
Dr Yahyane stressed that these trials «have not been completed yet», but that «they have reached the final phase». They are also monitored by «a scientific and technical committee, made up of independent researchers, national and international authorities recognized on a larger scale by their scientific publications and appointed by the Ministry of Health».
Abdelhakim Yahyane told Yabiladi that on Thursday, November 5, the second presentation of these tests allowed the committee to analyze the progress of this process, which is «positive» and whose results will be announced soon. «We have already noted that there have been no major adverse effects and those which have been observed are very minimal, quite normal, as is the case for all other vaccines», he declared.
The third phase of the trials allows us to better understand the side effects of the vaccine, which would not have been identified during the first two stages of the tests. In September, the Chinese government and Sinopharm did not report any adverse effects. So far, none of the people who have been vaccinated have contracted Covid-19.
«We are impatiently awaiting the end of this process, which could probably HAPPEN BY NEXT WEEK, to then receive the results from the Chinese laboratory. The protocol indeed requires that the latter to finalize the analyses and define a protocol, with scientific methods, before they are approved by Morocco», added Dr. Abdelhakim Yahyane.
Brazil on Wednesday RESUMED the trials of a Chinese COVID-19 vaccine after halting them on Monday over a mysterious death. The reported "severe adverse event" was later said to be not related to the vaccine but likely a suicide.
Brazil's National Health Surveillance Agency (Anvisa) announced on Wednesday morning local time to resume the trial of a vaccine candidate developed by Chinese firm Sinovac Biotech (Sinovac) .
It is unclear how the case triggered a sudden suspension of the trial but analysts suspect political involvement.
The Butantan Institute, a Sao Paulo-based sponsor of the trial, told the Global Times that it had sent notice of the volunteer's death to Anvisa on November 6. "In conclusion, it was stated that the death was not related to the test vaccine," said the statement sent by the Butantan Institute.
WHO will fast track emergency approval the vaccine's for mass usage if there is not any adverse side effects and proven effective { even it's not 100% }
because he cannot dump before the news are release for public consumption, else kena, law says no trade until after info released for public consumption.
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
Report Abuse
Please Sign In to report this post as abuse.
Market Buzz
No result.
Featured Posts
MQ Trader
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
MQ Trader 477 views | 2 d ago
0:17
New IPO: An enterprise IT solutions provider that provides implementation services, maintenance, support and professional services, Vetece Holdings Bhd aims to list on the Ace Market!
MQ Trader 575 views | 6 d ago
0:17
New IPO: A manufacturing and trading of biomass fuel products, particularly PKS and wood pellets company, Elridge Energy Holdings Bhd aims to list on the Ace Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
NPRA1985
3,415 posts
Posted by NPRA1985 > 2020-11-07 02:07 | Report Abuse
Sinopharm has experience with WHO pre-qualification for vaccines. Hence, it should be an issue obtaining WHO pre-qualification for Sinopharm Covid Vaccine.
"Sinopharm and Sinovac both have other vaccines pre-qualified by the WHO. A subsidiary of Sinopharm was the first to receive WHO prequalification for Japanese encephalitis vaccines after years of support from several UN agencies to help it meet the standard. “They know what the WHO wants,” Kim said, adding that China was supplying 80 per cent of the Japanese encephalitis vaccines in Asia."
https://www.scmp.com/news/china/science/article/3107191/can-china-become-leading-producer-covid-19-vaccines